Browsing Tag
Nivolumab
14 posts
Replimune (REPL) soars 86% as WSJ says White House intervention reopens RP1 review
Replimune jumped nearly 86% after the WSJ reported White House officials pushed the FDA to reconsider twice-rejected RP1. A reopened path, and a binary bet on approval.
Bristol Myers Squibb (NYSE: BMY) expands Opdivo into frontline Hodgkin lymphoma, strengthening immuno-oncology leadership
Bristol Myers Squibb expands Opdivo in Hodgkin lymphoma. Discover how this reshapes treatment strategy, competition, and long-term oncology trends.
CEL-SCI advances Multikine study with FDA nod, eyes non-dilutive funding for commercial push
CEL-SCI Corporation has taken a significant step toward commercializing its investigational Multikine neoadjuvant therapy, as the U.S. Food…
Bristol Myers Squibb’s Opdualag fails to meet primary endpoint in Phase 3 trial
Bristol Myers Squibb has announced that its Phase 3 RELATIVITY-098 clinical trial, designed to evaluate Opdualag (nivolumab and…
Study results spark 13% drop in Perspective Therapeutics shares – Radiation levels in focus
Shares of Perspective Therapeutics (NYSE AMERICAN: CATX) fell sharply, dropping over 13% to $11.49, after the latest data…
Bristol Myers Squibb’s subcutaneous nivolumab shows promise in Phase 3 RCC trial
Bristol Myers Squibb (NYSE: BMY) has announced results from its Phase 3 CheckMate -67T trial, which could revolutionize…
FDA approves Opdivo and Cabometyx combo for advanced kidney cancer treatment
The U.S. Food and Drug Administration (FDA) has officially approved the combination of Bristol Myers Squibb’s Opdivo (nivolumab)…
OncoSec Medical begins phase 2 trial for TAVO and OPDIVO combination in melanoma treatment
OncoSec Medical, a US-based biotechnology company, has officially dosed the first patient in its phase 2 clinical trial,…
Bristol Myers Squibb’s Opdivo receives EC approval for second-line treatment of ESCC
Bristol Myers Squibb (BMS) has achieved a significant milestone with the approval of its immunotherapy drug, Opdivo (nivolumab),…
Bristol Myers Squibb’s Opdivo and Yervoy combination approved for metastatic NSCLC in Europe
Bristol Myers Squibb (BMS) has announced a major breakthrough in cancer treatment with the European Commission’s (EC) approval…